Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

This study is testing a new immunotherapy drug called OSE-279 in patients with advanced solid tumors or lymphomas. In one part of the study, the focus is specifically on advanced non-small cell lung cancer (NSCLC) with high expression of PD-L1. The drug works by boosting the immune system's ability to recognize and attack cancer cells. **You may be eligible if...** - You are 18 or older - You have Stage IV non-squamous or squamous NSCLC without certain targetable gene mutations (EGFR, ALK, ROS1) - Your tumor has high PD-L1 expression (TPS ≥50%) - You have not had any prior systemic treatment in the first-line metastatic setting - You have at least one measurable tumor and adequate organ function **You may NOT be eligible if...** - Your cancer has EGFR, ALK, ROS1, or other targetable mutations - You have active autoimmune disease or are on chronic immunosuppressants - You are pregnant or breastfeeding - You have received prior immunotherapy for metastatic NSCLC Talk to your doctor to see if this trial is right for you.